Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOD1 | P00441 | 3/20 | 0.52 |
| ▸ | QPCT | Q16769 | 6/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033308 | 0.82 | SOD1 (0.52) | SOD1QPCTTBXAS1ALDH1A1ALOX15 | |
| SCHEMBL8365568 | 0.77 | TBXAS1 (0.59) | SOD1QPCTTBXAS1ALDH1A1L3MBTL1 | |
| SCHEMBL14504174 | 0.75 | ALOX15 (0.52) | SOD1QPCTALDH1A1ALOX15L3MBTL1 | |
| SCHEMBL31436074 | 0.75 | NAMPT (0.50) | QPCTALDH1A1L3MBTL1TSHR | |
| SCHEMBL806605 | 0.73 | TBXAS1 (0.63) | SOD1QPCTTBXAS1ALDH1A1L3MBTL1 | |
| SCHEMBL19786259 | 0.73 | TBXAS1 (0.68) | SOD1QPCTTBXAS1ALDH1A1ALOX15 | |
| SCHEMBL13766459 | 0.72 | TBXAS1 (0.62) | QPCTTBXAS1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL28286843 | 0.72 | TBXAS1 (0.68) | SOD1QPCTTBXAS1ALDH1A1L3MBTL1 | |
| SCHEMBL13256613 | 0.72 | QPCT (0.65) | SOD1QPCTTBXAS1ALDH1A1L3MBTL1 | |
| SCHEMBL11495035 | 0.72 | SOD1 (0.67) | SOD1QPCTALDH1A1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217001-B2 | Modification of feeding behavior | IMPERIAL INNOVATIONS LIMITED | 2012-07-10 | — | — | US | disclosed |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | IMPERIAL COLLEGE INNOVATIONS LTD. (GB) | 2009-08-20 | — | — | US | disclosed |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2008-02-21 | — | — | US | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| EP-1816127-A1 | TRIAZINE DERIVATIVES FOR USE AS SELECTIVE NPY (Y5) ANTAGONISTS | H. Lundbeck A/S (DK) | 2007-08-08 | — | — | EP | disclosed |
| US-7189720-B2 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2007-03-13 | — | — | US | disclosed |
| US-6989379-B1 | Selective NPY (Y5) antagonists | H. LUNDBICK A/S (DK) | 2006-01-24 | — | — | US | disclosed |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | H. LUNDBECK A/S (DK) | 2005-08-11 | — | — | US | disclosed |
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6569856-B2 | Treatment of feeding disorders, obesity, bulimia nervosa, sexual/reproductive disorders, depression, epileptic seizure, cardiovascular disorders, sleep disturbances | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019050-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | SOD1 4797/4885QPCT 387/4885TBXAS1 527/4885 |
| US-20090209461-A1 | MODIFICATION OF FEEDING BEHAVIOR | NPY4R, NPY5R, NPY2R | SOD1 4219/4885QPCT 253/4885TBXAS1 2456/4885 |
| US-20080045524-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | SOD1 4840/4885QPCT 293/4885TBXAS1 703/4885 |
| US-20020103201-A1 | Selective NPY (Y5) antagonists (triazines) | NPY5R, NPY1R, NPY2R | SOD1 4797/4885QPCT 387/4885TBXAS1 527/4885 |
| US-20050176709-A1 | Selective NPY (Y5) antagonists | NPY5R, NPY1R, NPY2R | SOD1 4840/4885QPCT 293/4885TBXAS1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.